Raquel Luque

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Raúl Ortíz, Gloria Perazzoli, Laura Cabeza et al. · Current Neuropharmacology · 2020 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 107 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

Carmen Balañá, Juan Manuel Sepúlveda-Sánchez, Miguel Gil‐Gil et al. · Journal of Neuro-Oncology · 2016 · 55 citations

Medicine, Oncology, Pharmacology +17

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

Anna Estival, Carolina Sanz, José Luis Ramírez et al. · Scientific Reports · 2019 · 43 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program

Daniel Castellano, Luis Aparicio, Emilio Esteban et al. · Expert Opinion on Drug Safety · 2014 · 28 citations · Full text

Medicine, Oncology, Pharmacology +16